# Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

> **NCT04322578** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Crizotinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04322578
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-24
- **Primary completion:** 2025-03-24
- **Final completion:** 2026-03-24
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322578, "Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04322578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*